The CMDh (Coordination Group for Mutual Recognition and Decentralised Procedures—Human) has approved new measures on the use of hydroxyzine in patients at high risk of heart rhythm problems. These measures, which encompass restrictions in use and dose, will be directly implemented by the Member States where the medicines are authorized, according to an agreed timetable.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
